WASHINGTON (Reuters) - U.S. Food and Drug Administration staff questioned the effectiveness of Adeza Biomedical Corp.'s Gevista drug because new findings were at odds with an earlier government-funded trial, according to documents released on Monday.>>> Discuss This Story
